Home > JCT>
Biography


Prof. Eva Corey

University of Washington, USA


Email: ecorey@u.washington.edu


Qualifications


1989 Ph.D., Czechoslovak Academy of Sciences, Czechoslovakia

1987 M.Sc., Charles University, Czechoslovakia

1985 B.Sc., Charles University, Czechoslovakia


Publications (selected)

  1. Corey E, Buhler KR, Vessell’a RL. Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology 1997:50;567-572.
  2. Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CFY, Ellis WJ, Vessella RL. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction (RT-PCR) of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997:50;184-188.
  3. Corey E, Wegner SK, Stray JE, Corey MJ, Arfman EW, Lange PH, Vessella RL.  Characterization of ten new monoclonal antibodies against prostate-specific antigen by affinity, specificity and function in sandwich assays.  Int J Cancer 1997;71:1019-1028.
  4. Corey E, Wegner SK, Corey MJ, Vessella RL. Prostate-specific antigen: Characterization of epitopes by synthetic peptide mapping and inhibition studies.  Clin Chem 1997;43:575-584.
  5. Gersuk GM, Corey MJ, Corey E, Stray EJ, Kawasaki GH, Vessella RL.  High-affinity peptide ligands to prostate-specific antigen (PSA) identified by polysome selection. Biochem Biophys Res Commun 1997;32:578-582.
  6. Corey E, Arfman EW, Liu AY, Vessella RL.  Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal control for prostate-specific antigen mRNA in blood and bone marrow.  Clin Chem 1997; 3:443-452.
  7. Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, Lange PH, Vessella RL. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997;3:249-256.
  8. Liu AY, Corey E, Vessella RL, Lange PH, True LD, Huang GM, Nelson PS, Hood L.  Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancer. Prostate 1997;30:145-153.
  9. Corey E and Corey MJ. Detection of disseminated prostate cells by RT-PCR: Technical and clinical aspects. Int J Cancer 1998;77: 655-673.
  10. Corey E, Arfman EW, Oswin MM, Melchior SW, Tindall DJ, Young CFY, Ellis WJ, and Vessella RL. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction (RT-PCR) of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997;50:184-188.
  11. Ellis WJ, Vessella RL, Corey E, Arfman EW, Oswin MM, Melchior SW, and Lange PH. The value of a reverse-transcriptase polymerase chain reaction assay in patients with prostate cancer. J Urol  1998;159:1134-1138.
  12. Corey E, Brown LG, Corey MJ, Buhler KR, and Vessella RL. The LNCaP prostate cancer cell line produces both putative zymogen and inactive, free form of prostate specific antigen. Prostate 1998;35:135-143.
  13. Corey E and Corey M. RT-PCR detection of prostate cells. Int J Cancer 1998;77:655-673.
  14. Buhler KR, Corey E, Stray JE, and Vessella RL. Study of free and complexed prostate specific antigen in mice bearing human prostate cancer xenograft. Prostate 1998;6:194-200.
  15. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, and Vessella RL. Osteoprotegerin and osteoclast differentiation factor expression in prostate cancer. Urology 2001;57: 611-616.
  16. Brown JM, Kostenuik PJ, Dunstan CR, Vessella RL, and Corey E. Serum osteoprotegerin levels are elevated in patients with advanced prostate cancer. Clin Cancer Res 2001;10:2977-2983.
  17. Corey E, Quinn JE, Vessella RL, Buhler KR, Roudier M, Brown LG, Brown JM, and Bladou F. Establishment and characterization of osseous prostate cancer model: direct intratibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
  18. Corey E, Quinn JE, Buhler KR, Brown LG, and Vessella RL. Inhibition of androgen-independent growth of prostate cancer estradiol. bxenografts by 17 Clin Cancer Res 2002;8:1003-100-107.
  19. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, and Vessella RL. Zoledronic acid exhibits anti-tumor effects on prostate cancer cells in vivo. Clin Cancer Res 2003 1: 295-306.
  20. Brubaker KD, Thomas R, Vessella RL, True LD, and Corey E. Expression and activity of Cathepsin K in prostate cancer. J Bone Min Res 2003;18:222-230.
  21. Corey E, Quinn JE, Buhler KR, Nelson PS, Machoska JA, True LD, and Vessella RL. LuCaP 35 : a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-246. (ISI: 46 citations)
  22. Pfitzenmaier J, Vessella RL, Higano CS, Noteboom J, Walace D.Jr., and Corey E. Advanced prostate cancer patients present with elevated levels of cytokines. Cancer 2003;97:211-1216.
  23. Wang Z, Corey E, Hass GM, Higano CS, True LD, Wallace D, Konicek BW, Tisdale MJ, and Vessella RL. Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. Int J Cancer 2003;105:123-129.
  24. Brubaker KD, Brown LG, Vessella RL, and Corey E. Osteoblast specific factor runx-2 is expressed in prostate cancer. Prostate 2003;56:13-22. (ISI:38 citations)
  25. Corey E, Quinn JE, and Vessella RL. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 2003;56:110-114.
  26. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, and Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Min Res 2003;18:1882-1888.
  27. Brubaker KD, Corey E, Brown LG, and Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2003;91:151-160.
  28. Roudier MP, Corey E, True LD, Higano Cs, Ott SM, Vessella RL. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res 2004;118:311-339.
  29. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RS, Higano CS, Ho SM, Vessella, RL, and Corey E. Metastases of prostate cancer express estrogen receptor beta. Urology 2004;64:814-820. (ISI:23 citations)
  30. Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, and Corey E. The effects of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP23.1 prostate cancer xenograft. Clin Exp Metastasis 2004;21:381-387.
  31. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TM, Blair JM, and Vessella RL. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005;65:1710-1718.
  32. Brown JE, Brown LG, Zhang J, Keller ET, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer and Prostatic Diseases 2005;8:253-259.
  33. Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, and Vessella R. Targeted chemotherapy with cytotoxic bombesin analoque AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer 2006;118:222-9.
  34. Brubaker KD, Brown LG, Vessella RL and Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;6:15.
  35. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, and Corey E. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with the increased expression of immune-related genes. Neoplasia 2006;8:862-78.
  36. Vessella RL and Corey E. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin Cancer Res 2006;12:6285s-6290s.
  37. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella RL, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6216s.
  38. Corey E.  Estrogen and prostate: Friend or foe. Current Cancer Therapy Reviews 2006;2:341-351.
  39. Emami KH and Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett 2007;253:170-179.
  40. Morrissey CM, Kostenuik PJ,  Brown LG, Vessella RL, Corey E. Host-Derived RANKL is Responsible for Osteolysis in C4-2 Human Prostate Cancer Xenograft Model of Experimental Bone Metastases. BMC Cancer 2007;7:148.
  41. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, Hunter M, Fairlie WD, Lee NJ, Enriquez RF, Baldock PA, Corey E, Apple FS, Murakami MM, Lin EJ, Wang C, During MJ, Sainsbury A, Herzog H, Breit SN. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med, 2007, 13:1333-1340.
  42. Morgan TN, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.  Prostate. 2008; 68:861-871.
  43. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.  Clin Exp Metastasis 2008, 25:377-388.
  44. Morgan TM, Koreckij T, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009;9:237-249. PMC2921605
  45. Trauger R, Corey E, Bell D, White S, Garsd A, Stickney D, Reading C, Frincke J. Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235). Br J Cancer. 2009;10:1068-1072. PMC2669987